WO2015002347A1

WO2015002347A1 - Liquid-phase antioxidant composition comprising kalanchoe extract for after-treatment following photodynamic therapy

Info

Publication number: WO2015002347A1
Application number: PCT/KR2013/009510
Authority: WO
Inventors: 서정훈; 신동규
Original assignee: 제너럴바이오(주)
Priority date: 2013-07-02
Filing date: 2013-10-24
Publication date: 2015-01-08
Also published as: KR20150004092A

Abstract

The present invention relates to a liquid-phase antioxidant composition comprising kalanchoe extract for after-treatment following photodynamic therapy (PDT) which decomposes or removes residual photosensitive substances during the application of an ALA composition for PDT that is used for ameliorating acne, etc. In addition, the composition can be easily applied to the skin due to having a liquid-phase formulation, and is expected to be capable of rapidly reacting with, and decomposing and removing, photosensitive substances absorbed in the skin. The ingredients of the composition consist of: purified water 64.8 wt% - 98.8 wt%; Ultrez 21 0.2 wt% - 0.6 wt%; hyaluronic acid 0.1 wt% - 1.0 wt%; glycerin 0.1 wt% - 20.0 wt%; kalanchoe extract 0.1 wt% - 10.0 wt%; 1,2-hexanediol 0.5 wt% - 3.0 wt%; and triethanolamine 0.2 wt% - 0.6 wt%.

Description

Antioxidant Liquid Composition Containing Kalanchoe Extract for Postoperative Photodynamic Therapy

The present invention relates to an antioxidant liquid composition comprising an extract of Kalanchoe for photodynamic treatment after treatment (PDT), and more particularly, to the skin generated during application of the ALA composition for treating PDT used for acne improvement. The present invention relates to a composition for relieving skin troubles such as erythema and decomposing or removing remaining photosensitive substances.

Photodynamic therapy (hereinafter referred to as 'PDT') is a technology that can treat intractable diseases such as cancer without performing surgery by using photosensitizer that has selectivity and photoactivity for cancer cells or various tumors. As one of them, unlike chemotherapeutic agents, it is a breakthrough tumor treatment with little side effects.

Recently, PDT treatment has been widely used for acne treatment and improvement.

The treatment of PDT used in acne treatment, amelioration, and the like, include levlan PDT, and the main component of the levlan drug in the levlan PDT is 5-aminolevulinic acid (ALA). That is why some people call it ALA PDT just to talk about its ingredients.

The levlan PDT is a treatment method that removes acne bacteria and sebaceous glands by applying ALA-containing medicine (Levlan) to the face and irradiating a laser.

After applying ALA-containing levlan and irradiating the laser, it is necessary to remove ALA-containing levlan from the skin after treating PDT for acne treatment and improvement.The ALA absorbed by the skin is not removed but remains on the skin. do.

Remaining ALA as described above has a problem that can cause side effects, such as erythema by stimulating the skin.

[Preceding technical literature]

[Patent Documents]

(Patent Document 1) (KR) Unexamined Patent Publication No. 10-2005-0027197

(Patent Document 2) (KR) Unexamined Patent Publication No. 10-2010-0114425

It is an object of the present invention to provide a neutralizing composition that decomposes or removes a photosensitive material remaining upon application of an ALA composition for treating PDT used for acne improvement.

Antioxidant liquid composition for photodynamic treatment post-treatment of the present invention for achieving the above object is 64.8% to 98.8% by weight purified water, 0.2% to 0.6% by weight Ultrez 21,

0.1 wt% to 1.0 wt% of hyaluronic acid, 0.1 wt% to 20.0 wt% of glycerin, 0.1 wt% to 10.0 wt% of kalancoe extract, 0.5 wt% to 3.0 wt% of 1,2-hexanediol, and 0.2 wt% of triethanolamine It is characterized by consisting of% to 0.6% by weight.

Liquid formulation composition for neutralizing photosensitive material of the present invention as described above As can be seen that the concentration of ALA is changed as in the experiment using Examples 1 to 3, the photosensitive substance neutralizing liquid formulation of the present invention is an ALA composition for treating PDT. There is an effect of decomposing or removing the photosensitive material remaining when the application of, thereby solving the problem caused by the remaining ALA composition.

In addition, the liquid formulation is easy to apply to the skin, it will be able to quickly react with the photosensitivity absorbed by the skin to decompose and remove.

In addition, after the PDT treatment, in removing the remaining ALA concentrations, problems caused by PDT treatment such as erythema phenomenon have been shown to suppress skin troubles coming from the erythema.

1 is a table of changes in ALA remaining amount when added to the ALA composition according to Example 1

2 is a table of changes in ALA remaining amount when added to the ALA composition according to Example 2

3 is a table of changes in ALA remaining amount upon addition to the ALA composition according to Example 3;

4 is a table showing changes in the amount of ALA remaining after 30 minutes of addition to the ALA composition according to Example 1. FIG.

5 is a table showing changes in ALA remaining after 30 minutes of addition to the ALA composition according to Example 2. FIG.

6 is a table showing changes in the amount of ALA remaining after 30 minutes of addition to the ALA composition according to Example 3. FIG.

Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings. Prior to this, terms or words used in the present specification and claims should not be construed as being limited to the common or dictionary meanings, and the inventors should properly explain the concept of terms in order to best explain their own invention. Based on the principle that can be defined, it should be interpreted as meaning and concept corresponding to the technical idea of the present invention.

Therefore, the embodiments described in the specification and the drawings shown in the drawings are only the most preferred embodiment of the present invention and do not represent all of the technical idea of the present invention, it can be replaced at the time of the present application It should be understood that there may be various equivalents and variations.

Antioxidant liquid composition for treatment after photodynamic therapy of the present invention is the composition of the ALA concentration change material remaining when the ALA composition for PDT treatment is as shown in Table 1 below

64.8 wt% to 98.8 wt% purified water, 0.2 wt% to 0.6 wt% Ultrez 21,

0.1 wt% to 1.0 wt% of hyaluronic acid, 0.1 wt% to 20.0 wt% of glycerin, 0.1 wt% to 10.0 wt% of kalancoe extract, 0.5 wt% to 3.0 wt% of 1,2-hexanediol, 0.2 wt% of triethanolamine It consists of% to 0.6% by weight.

Table 1

Example.

Mix each of the following composition ratios as shown in Table 2 below.

Formulation Order

Water-> Ultrez 21 (1 hour)-> Hyaluronic Acid-> Glycerin-> Kalanchoe Extract-> 1,2-hexanediol-> Triethanolamine

TABLE 2

* Numerical value of Table 2 means weight%

In addition, using the composition of each of Examples 1 to 3 consisting of the composition ratio of Table 2 was performed according to the ALA concentration change in the following manner.

1. According to each embodiment, 1 ml of the photosensitive neutralizing composition used in the PDT procedure is placed in 10 ml of 15% ALA composition for PDT treatment and vortexed.

2. Sample a small amount of the vortex composition of 1 and dilute 99 times. (Based on 0.1% concentration.)

3. Into a 10ml test tube, vortex 20 ml of the two diluted samples and 0.1ml Methylacetoacetate in 1ml of 1M Acetate Buffer (pH 4.7).

4. After heating to 90 ℃ for 10 minutes, cool down to room temperature (15 ℃).

5. Add 2 ml Ehrlich's reagent and vortex.

6. After 10 minutes, the remaining amount of ALA was investigated by using the UV spectrum, and the remaining amount of ALA was measured and illustrated after adding the ALA concentration and the neutralizing composition at the existing concentration.

1 is a table showing the change in the amount of ALA remaining when the liquid composition for neutralizing the photosensitive substance comprising the composition ratio of Example 1 is added to the ALA composition used in the PDT procedure;

FIG. 2 is a table showing changes in the amount of ALA remaining when a liquid formulation composition for neutralizing a photosensitive material comprising the composition ratio of Example 2 is added to an ALA composition used in a PDT procedure.

FIG. 3 is a table showing changes in the amount of ALA remaining when a liquid formulation composition for neutralizing a photosensitive material including the composition ratio of Example 3 is added to an ALA composition used in a PDT procedure.

As shown in the graphs of FIGS. 1 to 3, it can be seen that the residual amount of ALA concentration does not remain after the addition of the composition as compared to the standard, and when Examples 1 to 3, which are antioxidant compositions according to the change in the concentration of ALA, are added, In contrast, as it can be seen that the remaining ALA concentration of 53% to 20%, the composition of the present invention can be seen that the effect on the residual ALA concentration.

FIG. 4 is a table showing changes in the amount of ALA remaining 30 minutes after the addition of the liquid-sensitive composition for neutralizing the photosensitive material, which is composed of the composition of Example 1, to the ALA composition used in the PDT procedure.

FIG. 5 is a table showing changes in the amount of ALA remaining after 30 minutes of addition of the liquid composition for neutralizing a photosensitive material comprising the composition ratio of Example 2 to the ALA composition used in the PDT procedure.

FIG. 6 is a table showing changes in the amount of ALA remaining after 30 minutes after the addition of the liquid-sensitive composition for neutralizing the photosensitive material comprising the composition ratio of Example 3 to the ALA composition used in the PDT procedure.

As shown in the graphs of FIGS. 4 to 6, it can be seen that the remaining amount of ALA does not remain even after elapse of time, and when Examples 1 to 3, which are antioxidant compositions according to the change in ALA concentration, are added, the ALA concentration is compared with the reference. As it can be seen that the remaining amount of ALA concentration of 26% to 13%, it can be seen that the composition of the present invention is effective in the residual amount of ALA concentration.

In addition, after removing PDT treatment, in removing the residual ALA concentration, problems caused by PDT treatment, such as erythema, have been shown to have an effect of suppressing skin troubles coming from erythema. The experimental value of the composition containing the excellent effect on the antioxidant is as follows.

The most distinctive mechanism of antioxidants is the reaction with free radicals. Free radical scavenging is used as a measure to inhibit the aging effects in plants or the antioxidant effect of plants by donating electrons to free radicals.

In the following experiment, the antioxidant activity was measured by using the DPPH method to verify the antioxidant efficacy of the Examples 1 to 3 containing Kalanchoe extract.

40 μL of each composition was added to 760 μL of 300 μM DPPH / EtOH, and then left at 37 ° C. for 30 minutes, and then absorbance was measured at 518 nm using a UV / Vis spectrophotometer (GENESYS 10S Vis Spectrophotometer).

The empirical formula for deriving antioxidant activity is as follows.

To this end, by measuring the absorbance of each composition, it is to derive the respective antioxidant degree.

Antioxidant degree (%) = {1- (absorbance of antioxidant addition spheres) / (absorbance of antioxidant addition spheres)} × 100

For each composition, the results of the experimental measurements under the same conditions together with the comparison object over four periods at approximately one week intervals at room temperature and 50 ° C., two temperature conditions are provided in Table 3.

TABLE 3

According to the experimental results of Table 3, the compositions of the present invention, as time passes from the first experimental date, compared to the antioxidant company H of the comparative example, up to 7 times at room temperature, up to 4 times the antioxidant at 50 ° C. The figure is shown.

In addition, looking at Table 3, it shows a comparison of the experimental value of the antioxidant composition between the three compositions of the present invention and the comparative example at room temperature, Looking at this, the composition of the present invention is the change of the antioxidant degree with respect to the initial time over time 40% decrease, but the comparative example shows an antioxidant degree that is reduced by 80%.

In addition, looking at Table 3, it shows a comparison of the experimental value of the antioxidant composition between the present invention and the comparative example of the three compositions at 50 ° C, as in the above room temperature, even if the period elapsed compared to the commercial antioxidant products of the comparative example In addition, it shows relatively good results in the reduction of antioxidant level. In addition, at the same time in the antioxidant degree of the comparative example, up to 3.8-fold antioxidant activity was shown to be high, and this trend shows that the stability of the antioxidant substance is higher than the comparative example with time.

In the case of the composition of the present invention, the reduction in the degree of antioxidant is very small compared to the initial value even when the period elapses, compared to the initial value, and shows a very stable antioxidant value over time, which indicates the antioxidant efficacy according to use. It is a very important measure.

In addition, vitamin C is a result measured to verify the stability of the test sample during the measurement, and the results of the Kalanchoe extract undiluted solution showed good stability at room temperature and high temperature and can be used as a cosmetic formulation. Accordingly, the antioxidant containing the extract of Kalanchoe as an antioxidant may be shown to be superior to the antioxidant-added products on the market as a result of measuring the activation at room temperature and high temperature.

Claims

64.8 wt% to 98.8 wt% purified water, 0.2 wt% to 0.6 wt% Ultrez 21,

0.1% to 1.0% by weight of hyaluronic acid, 0.1% to 20.0% by weight of glycerin, 0.1% to 10.0% by weight of kalanchoe extract, 0.5% to 3.0% by weight of 1.2-hexanediol,

An antioxidant liquid composition comprising an extract of Kalanchoe for Photodynamic Therapy Post-Treatment (PDT) consisting of 0.2% to 0.6% by weight of triethanolamine.
The method of claim 1,

The composition is easy to apply to the skin by being in a liquid formulation, kalancoe for photodynamic therapy post-treatment (PDT) is characterized in that it comprises a feature that can quickly react with the photosensitivity absorbed by the skin to decompose and remove Antioxidant liquid composition containing the extract.